Abstract. Many macropodids exhibit lactational quiescence during which an embryo produced at post-partum mating is retained as a blastocyst in utero while a pouch young is sucking. The sucking stimulus maintains secretion of prolactin which may in some species inhibit the activity of the corpus luteum and, hence, the development of the embryo. When the sucking frequency decreases, the blastocyst resumes development. In the present study, the doparnine agonist bromocriptine, which in many mammals results in decreased secretion of prolactin from the pituitary gland, was administered to the Tasmanian bettong (Bettongia gaimardi) at two different doses (12.5 mg kg-' and 5 mg kg-'). Although lactation was affected by both doses, as evidenced by slower growth of the pouch young or their loss, in only two cases did the quiescent blastocyst activate at the time of injection. This occurred with the highest dose of bromocriptine and was reflected by earlier changes in plasma progesterone concentrations. It is concluded that the Tasmanian bettong is unusual in its lack of sensitivity to bromocriptine.
Introduction
After birth, most macropodid marsupials (kangaroos, wallabies and rat-kangaroos) have a post-partum oestrus and mating. If fertilization occurs, the corpus luteum remains quiescent so that the blastocyst enters embryonic diapause. In most species, this quiescence is controlled by the presence of a sucking young in the pouch and is termed 'lactational quiescence'. Removal of the pouch young (RPY) results in the resumption of embryonic growth (Shaman 1970) , as does severing the afferent connection from the mammary gland (Renfree 1979) . Tyndale-Biscoe and Hawkins (1977) and Curlewis and Loudon (1988) showed that, in the tammar (Macropus eugenii) and Bennett's wallaby (M. rufogriseus), injection of prolactin for seven days after RPY inhibited embryonic development for a similar period of time. It is presumed that prolactin, produced in response to the sucking stimulus, acts to suppress the corpus luteum and, consequently, embryonic development in most macropodids.
In macropodids, therefore, administration of the dopamine agonist bromocriptine, which suppresses prolactin secretion in most species, would be expected to stimulate the development of the quiescent blastocyst. Wallace and Renfree (1980) observed such an effect with the quokka (Setonix brachyurus). Tyndale-Biscoe and Hinds (1984) injected bromocriptine into tammar wallabies carrying pouch young during lactational quiescence and observed that the blastocysts reactivated. Similar results were obtained in the Bennett's wallaby (Curlewis et al. 1986 ). However, the tammar and Bennett's wallaby are distinctly seasonal breeders. When young are lost or removed experimentally during the non-breeding season, the quiescent blastocyst does not reactivate: this time is termed 'seasonal quiescence'. When bromocriptine was injected later in pouch life during seasonal quiescence no effect was detected. More recently, Hinds and Tyndale-Biscoe (1994) injected bromocriptine at midto-late lactation into two species of grey kangaroo (the eastern, Macropus giganteus and the western, M. fuliginosus) that are seasonal breeders in their southern range. They found that when given 'high' doses (5 mg kg-') or long-acting doses of bromocriptine, most pouch young lost weight and subsequently died. The western grey females did not give birth until the normal summer breeding season, but the eastern grey females gave birth 2-4 months early.
To date, the effect of bromocriptine during late pouch life in continuously-breeding macropodids has not been investigated. The Tasmanian bettong (Bettongia gaimardi) is a small macropodid endemic to Tasmania and is a continuous breeder (Rose 1987) . Reproductive cycles can be induced in the Tasmanian bettong by RPY thereby releasing the corpus luteum from its prolactin-induced inhibition (Rose 1986 ). Birth and/or oestrus follow RPY by 17.6% 0 . 9 days and 1 8 . 9 f 1 . 3 days, respectively, the ranges for these two events being 16-19 days and 17-22 days respectively. In this species, the diapausing embryo is reactivated towards the end of pouch life, presumably in response to the reduced duration or intensity of suckling. The large furred pouch young is excluded from the pouch during the night of birth and post-partum oestrus by a strong prolonged contraction of the pouch musculature (Rose 1986) .
The hormonal events associated with birth andlor oestrus in this species and similar species may therefore also be involved in the control of pouch contraction and the subsequent exclusion of the pouch young (Shaman and Calaby 1964; Rose 1986 ). This hypothesis could be further tested by manipulating the reproductive cycle so that the hormonal 'milieu' of birth and/or oestrus occurred before the normal time of pouch vacation: in such circumstances, pouch vacation could be expected to occur prematurely. We predicted that, in bettongs, the injection of bromocriptine before the normal reactivation of the diapausing blastocyst should block prolactindependent inhibition of the corpus luteum, initiate events leading to birth and also result in premature pouch vacation by the large pouch young. To test this proposal, bromocriptine was administered to Tasmanian bettongs with pouch young. In preliminary trials, bettongs were given 5 mg kg-' bromocriptine and blastocysts failed to reactivate (Rose 1984) ; hence, in the present study, some bettongs were given a higher dose of 12.5 mg kg-'.
Materials and Methods

Animals
The bettongs used in the present study were all obtained from the breeding colony maintained at the University of Tasmania in Hobart and had pouch young. Husbandry was as described in Rose (1982) . The ages of pouch young were determined before the experiment to ensure that no animal was injected after the period of natural reactivation of the quiescent blastocyst.
Experimental Procedure
All treatments were administered with a single, intramuscular injection of freshly made, warm bromocriptine (CB 154; Sandoz Australia) prepared in carrier (150 mg D,L-tartaric acid, 3 mL 70% ethanol and 3 mL 0.9% sterile saline) at 40-45"C, according to the manufacturer's instructions. Two doses were given: 5 mg kg-' (n = 4) or 12.5 mg kg-' (n = 7) -controls were injected with carrier alone (n = 7). All injections were administered between October 1991 and March 1992 which is spring-summer in the southern hemisphere.
Growth
Following the injection of bromocriptine or carrier alone, all bettong pouch young were weighed regularly until final pouch vacation. The instantaneous growth rate was calculated as follows, as described by Rose (1984 Rose ( , 1989 : natural log of final weight (g) -natural log of initial weight (g) time period (days) Thus, a single value was obtained for each animal. The growth rate during the period of pouch life examined in the present experiment is known to be linear (Rose 1989) . After treatment, mothers were examined regularly for new pouch young; they were examined daily from Day 14 to Day 28, thereby encompassing the normal delayed gestation length for this species. If no birth occurred during this time period, the animal was again examined for the evidence of birth when the original pouch young (if still present) vacated the pouch.
Plasma Progesterone Concentrations
Blood samples were obtained from the lateral tail vein from all mothers just before the injection of bromocriptine or control vehicle (Day 0) and on Days 4, 9, 14 and 19. Blood samples were not taken daily because daily blood sampling may affect the length of gestation in this species (Jones and Rose 1992) . Samples were placed on ice before the plasma was separated by centrifugation. Plasma samples were stored in vials at -20°C before analysis. Plasma progesterone concentrations were measured by radioimmunoassay as described by Jones and Rose (1992) .
Statistical Analysis
All data obtained, other than progesterone concentrations, were subjected to one-factor ANOVA to determine whether there was a treatment effect. Subsequently, the Fisher PLSD (probability of least significant difference) test was used to test for significant differences between individual treatments. Progesterone concentrations were analysed in a manner similar to that used by Hinds et al. (1990) . This involved subtracting the concentration of progesterone on Day 0 (before injections) from all other concentrations obtained for each animal, thereby allowing for the individual variations in initial concentrations of progesterone (Hinds et al. 1990 ). To equalize the change in values between animals, we then divided data by the initial concentration of progesterone; finally, loglo of the data was calculated to normalize the values. Thus transformed, the data was subjected to two-factor repeated-measures ANOVA. The aim of the analysis was to determine: (a) whether there was a treatment effect; and (b) whether progesterone concentrations were elevated earlier in the treatment groups (by comparison with each other and the control).
Results
Births
The results of bromocriptine administration to bettongs are presented in- Table 1 . Among the 7 bettongs given the high dose of bromocriptine, 2 of 7 gave birth 20-21 days after injection and 1 (animal no. 102) entered a reproductive cycle but did not give birth (presumably it had not been pregnant). One other gave birth 47 days after injection at what would be the usual time for that animal. The other 3 bettongs in this high-dose group failed to give birth, although 1 was observed mating on the day of final pouch vacation of her young. All 4 bettongs given the low dose of bromocriptine gave birth at the normal time coincident with final pouch vacation, none of the blastocysts reactivating at injection. In the control group of bettongs, 5 of 7 retained their pouch young for the normal period and, in 4 of these mothers, birth occurred at the normal time, coincident with pouch vacation. Of the remaining 2 control animals, 1 lost her young and the other mother died of unknown causes. 
Plasma Progesterone Concentrations
The mean values of plasma progesterone concentrations 
Growth in Pouch Young after Treatment
The effect of bromocriptine treatment on the growth rate of pouch young is shown in Table 2 . One-factor ANOVA gave a significant result for the effect of treatment on growth rate (d.f. = 2, 14; F = 4.875; P = 0.025). The Fisher PLSD test showed that the young in both of the experimental groups had significantly lower growth rates than those in the control group ( P > 0.05) but were not significantly different from each other. Four of the young in the high-dose group were lost but the 3 surviving pouch young grew at a normal rate and had achieved a normal weight at final pouch vacation. By contrast, although all young in the low-dose group survived to pouch vacation, their mean weight at this time was significantly lower than that of the young in the other two groups ( P = 0-02). The mean age at pouch vacation of young that survived varied little between the three groups (Table I) The interaction between the two effects was also significant ( P = 0.045). The post-hoc PSLD tests on treatment showed a significant difference ( P = 0.05) between the treatment groups and the control group, but not between the two treatment groups.
All groups showed an increase in plasma progesterone concentration on Day 4 but, for that day, the post-hoc PSLD tests on days showed that there was no significant difference between the groups ( P = 0.88). The posthoc analysis showed that both treatment groups had progesterone concentrations that were significantly higher than those of the control group on Day 9 ( P = 0.04) and Day 14 ( P = 0.02), but not on Day 19 ( P = 0.37) when there was considerable variation within the groups. By Day 19, irrespective of whether bromocriptine had an effect, one could assume that reproductive cycles had been initiated in most animals in the three groups because their 'natural' day of reactivation had passed.
The group receiving the high dose of bromocriptine was the only group in which births occurred as a result of reactivation of the corpus luteum at, or near, the time of injection and their individual progesterone profiles are shown in Fig. 2 . Animals no. 145 and no. 146 gave birth 20-21 days after injection and their plasma progesterone concentrations were elevated compared with those of animal nos. 143, 147, 184 and 190. However, animals no. 102 showed elevated concentrations of progesterone on Day 9-this is the animal whose pouch young lost weight immediately after injection of bromocriptine into its mother.
Discussion
If bromocriptine were to reduce prolactin sufficiently to remove the inhibition from the quiescent corpus luteum, it would be expected that birth andlor oestrus would occur approximately three weeks after injection. Among the bettongs investigated in the present study, only 2 of 18 gave birth within this period and both were in the high-dose group. In these animals, bromocriptine may have reduced prolactin secretion sufficiently to induce reactivation of the corpus luteum. Unfortunately, the lack of a suitable antiserum precluded measurement of plasma prolactin concentrations during the present study. The overall lack of births, coupled with the loss of pouch young, prevented the hypothesis that the hormonal 'milieu' at birth initiates pouch vacation from being tested.
Both treatment groups had lower growth rates than the control group, the growth rate of which was similar to that found by Rose (1989) for 17 pouch young. The lower growth rate in the low-dose group may be due to reduced plasma concentrations of prolactin inhibiting lactation, resulting in a significantly lower weight in young at pouch vacation. The results for the high-dose group were more variable; all pouch young with a reduced growth rate died, perhaps due to greater inhibition of prolactin, but some young were unaffected and grew normally, achieving a similar weight to that of the young in the control group when leaving the pouch.
If the oestrous cycle or pregnancy were initiated at the time of injection of bromocriptine, we would expect to detect the early pulse of progesterone in plasma found in all macropodids (Hinds and Tyndale-Biscoe 1982; Hinds 1989) . Normally this early pulse occurs on Day 4 after RPY in the Tasmanian bettong and concentrations remain elevated (1.2-1.5 ng mL-') after Days 6-7 (Jones and Rose 1992) . Thus, an animal in which the corpus luteum reactivated would be expected to have elevated plasma progesterone concentrations on Days 4, 9, 14 and 19 after injection of bromocriptine. None of the treatments resulted in a significant increase in the mean concentrations of progesterone at Day 4 (or Day 9) by comparison with those on Day 0. However, when the data from individual animals were examined, a trend emerged that was obscured by the variation about the means. Within the high-dose group, the two animals that gave birth as a likely response to the injection of bromocriptine (animals nos 145 and 146) demonstrated progesterone profiles that were normal for pregnancy, although the Day-4 peak may have been missed due to the infrequent sampling regimen. One other animal (no. 102) also had high concentrations of progesterone on Day 9 and Day 19 but did not give birth. This animal had a pouch young that appeared dehydrated on Day 9 after injection and had been lost by Day 14. In this mother, the injection of bromocriptine could well have caused a failure of lactation and she could have entered a reproductive cycle as a result of decreased suckling. In this case, loss of the pouch young may be a result of bromocriptine interference with the control of lactation. Similar losses of pouch young occurred after bromocriptine treatment in the tarnmar and Bennett's wallaby (Tyndale-Biscoe and Hinds 1984; Curlewis and Loudon 1988) as well as in both species of grey kangaroo (Hinds and Tyndale-Biscoe 1994) . In the Bennett's wallaby, the loss of pouch young was attributed to the decreased secretion of prolactin, secondary to bromocriptine interaction. If the loss of pouch young in the bettong was also due to prolactin inhibition, one might expect that diapause would have been terminated after the injection of bromocriptine.
It may be that prolactin was reduced but did not terminate quiescence. Curlewis et al. (1986) showed that, in the Bennett's wallaby, prolactin concentrations could be reduced by bromocriptine without termination of quiescence. To determine whether this may have occurred in the bettong would require measurement of prolactin concentrations. The bettongs may have demonstrated decreased prolactin secretion: this is suggested by the failure of lactation in some bettongs within 1-3 weeks of injection and the lighter weight of some young measured at final pouch vacation.
The relative lack of response to the injection of bromocriptine by the bettongs is difficult to explain. One difference between the bettong and other macropodids that have been treated 'successfully' with bromocriptine is that the bettong is a continuous breeder able to produce young throughout the year (Rose 1987) . However, it has been shown recently that, in the Tasmanian pademelon (Thylogale billardierii), a continuous breeder (Rose and McCartney 1982) , 8 of l l females responded to injections of bromocriptine (5 mg kg-') by initiating pregnancy and reproductive cycles (Rose, unpublished observations) .
It appears then, that control of lactational quiescence in the Tasmanian bettong may be under the control of a bromocriptine-inqensitive mechanism. Some human females are insensitive or resistant to bromocriptine used to reduce prolactin concentrations but are sensitive to newer forms of prolactiri,inhibitors such as 'Cabercoline' or 'Quinagolide' (Vilar ahd Burke 1994; Rains et al. 1995) . These drugs may also be effective in the bettong.
On the other hand, it may be that, in the bettong, prolactin is not under dopamine modulation (A. S. I. Loudon, personal communication) and that other factors may maintain prolactin secretion during treatment with bromocriptine. Lincoln and Clark (1994) have shown recently that, in the ram, the secretion of prolactin can be mediated via a dopamine-independent mechanism. It is well known from studies in the rat that constitutive secretion of prolactin, albeit at low levels, continues in the presence of dopamine suppression (Stirling and Shin 1990) . If this occurs in the bettong, a plausible explanation for our results might be that these low levels of prolactin are sufficient for the maintenance of quiescence but not for lactation; that is, there may be differences in responsiveness of the two processes (lactation and quiescence) to prolactin.
Further experiments involving measurements of the plasma concentrations of prolactin may assist in the explanation of the lack of effect on quiescence by bromocriptine in the bettong.
